Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.
about
ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpuraRituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test.Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura.Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.Management of thrombotic thrombocytopenic purpura: current perspectivesMultiple centre evaluation study of ADAMTS13 activity and inhibitor assays.ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.Thrombotic thrombocytopenic purpura
P2860
Q28083264-83F7DCA0-4099-40A7-8210-EA5313A21FBEQ33416588-56E0D10E-3E31-4AEF-9AFC-438B9588ECE4Q33421861-19DA7EEB-F9CF-4593-BCBF-0D9FC9EBECE5Q33426599-54F78E3B-D679-44FA-AB61-3898445CFEF7Q33434014-9A45A797-48FF-49A2-8DE0-AFAF7099D991Q33436972-03E7741A-7AA3-4B1A-BF2F-56B52EC38FB4Q33443111-CC79C617-3DAD-497B-BF53-6C8373D81B16Q34377532-9D3BA805-64EA-4800-92CB-7738108491F4Q35690203-AEE5F96E-510D-4F26-AEA1-58D11FDF1B56Q37577785-27172E1B-32BC-458C-BEB6-62948FE32FFBQ45873988-E30486A5-274A-49F0-873C-4A2ABB8A8646Q53275633-53770FF2-BACF-44B5-B056-C02978851F06Q57379903-EB61B964-9AF4-4262-8856-3F0D3D5BC0AC
P2860
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@ast
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@en
type
label
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@ast
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@en
prefLabel
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@ast
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@en
P2093
P356
P1476
Discrepancies between ADAMTS13 ...... thrombotic microangiopathies.
@en
P2093
Andrew Chitolie
Ian Mackie
Katy Langley
Marie Scully
Ri Liesner
Samuel Machin
P304
P356
10.1160/TH12-08-0565
P577
2013-01-10T00:00:00Z